SCHOTT Pharma Invests $371 Million in New US Facility for Prefillable Syringe Production

SCHOTT Pharma is set to open a new $371 mn manufacturing facility in Wilson, North Carolina, to produce prefillable syringes. The facility is aiming to commence operations in 2027, which will create 401 jobs and focuses on meeting U.S. demands for mRNA and GLP-1 therapy syringes to enhance the domestic supply chain. This expansion is expected to triple SCHOTT's U.S. output of these syringes by 2030, supporting faster delivery and reducing costs while bolstering pandemic preparedness and drug shortage defences.

The new site will expand the U.S. supply chain for in-demand syringes that deliver lifesaving injectable medicines, vaccines, and other fields of applications, allowing SCHOTT Pharma to triple its contribution of glass and polymer syringes to the U.S. market by 2030. Bringing production to the U.S. will reduce lead times and slash transportation costs, as well as protect against future shortages of critical drugs and ensure pandemic preparedness.

“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the U.S.,” said Andreas Reisse, CEO of SCHOTT Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”

The top 30 global pharma companies and more than 1,800 customers rely on SCHOTT Pharma containers and systems, including the U.S. and global leaders in the pharmaceutical and biotech categories. Many of these companies have designated SCHOTT Pharma as a critical supplier of one or more of the most essential components within their supply chain. On average, more than 25,000 injections per minute are provided to patients worldwide through a product produced by SCHOTT Pharma.

“Wilson County stood out in a nationwide search for a number of reasons, particularly for its favorable pool of local talent and its proximity to the Research Triangle area, which hosts numerous universities, healthcare companies, and biopharma resources,” said Christopher Cassidy, President of SCHOTT North America. “Expanding operations in the U.S. addresses rapidly growing demand for our high-value solutions.”

“North Carolina’s pro-growth and low-tax policies, along with the $40 million investment in the new biologics training facility at Wilson Community College, are paying off for Wilson County and the BioPharma Crescent,” said North Carolina Senator Buck Newton. “SCHOTT Pharma’s $371 million capital investment and 401 high-wage jobs will strengthen our local economy. We look forward to a long and successful future for them here in Wilson.

For over two decades, SCHOTT Pharma has been manufacturing vials at its Lebanon, PA, facility, serving as a reliable partner for the pharmaceutical industry. Being that the U.S. is a key strategic market for the entire SCHOTT Group, the company underwent a nationwide site selection process for a campus-like property to serve further growth opportunities. While SCHOTT is not guaranteeing additional investment to support other markets at this time, the site in Wilson, North Carolina offers the possibility of future expansion.

The project location is contingent on final real estate negotiations. SCHOTT Pharma partnered with several organizations throughout the project, including the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, the North Carolina General Assembly, the North Carolina Community College System, Commerce’s Division of Workforce Solutions, Wilson County, the City of Wilson, the Wilson Economic Development Council, the North Carolina Biotechnology Center, and the Biomanufacturing Training and Education Center at North Carolina State University.

For more, please find the original story source here.